PREVDUO Drug Patent Profile

When do Prevduo patents expire, and when can generic versions of Prevduo launch?

Prevduo is a drug marketed by Azurity and is included in one NDA. There are five patents protecting this drug.

The generic ingredient in PREVDUO is glycopyrrolate; neostigmine methylsulfate. There are seventeen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the glycopyrrolate; neostigmine methylsulfate profile page.

DrugPatentWatch^® Generic Entry Outlook for Prevduo

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be October 25, 2038. This may change due to patent challenges or generic licensing.

There have been four patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for PREVDUO

US Patents:	5
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Drug Prices:	Drug price information for PREVDUO
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for PREVDUO
What excipients (inactive ingredients) are in PREVDUO?	PREVDUO excipients list
DailyMed Link:	PREVDUO at DailyMed

See drug prices for PREVDUO

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for PREVDUO

NDA:

216903

Dosage:

SOLUTION;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for PREVDUO

Drug Class	Anticholinergic Cholinergic Muscarinic Antagonist Cholinesterase Inhibitor
Mechanism of Action	Cholinergic Antagonists Cholinergic Muscarinic Antagonists Cholinesterase Inhibitors

US Patents and Regulatory Information for PREVDUO

PREVDUO is protected by five US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Azurity	PREVDUO	glycopyrrolate; neostigmine methylsulfate	SOLUTION;INTRAVENOUS	216903-001	Feb 23, 2023		RX	Yes	Yes			Y
Azurity	PREVDUO	glycopyrrolate; neostigmine methylsulfate	SOLUTION;INTRAVENOUS	216903-001	Feb 23, 2023		RX	Yes	Yes			Y
Azurity	PREVDUO	glycopyrrolate; neostigmine methylsulfate	SOLUTION;INTRAVENOUS	216903-001	Feb 23, 2023		RX	Yes	Yes			Y
Azurity	PREVDUO	glycopyrrolate; neostigmine methylsulfate	SOLUTION;INTRAVENOUS	216903-001	Feb 23, 2023		RX	Yes	Yes			Y
Azurity	PREVDUO	glycopyrrolate; neostigmine methylsulfate	SOLUTION;INTRAVENOUS	216903-001	Feb 23, 2023		RX	Yes	Yes			Y

Market Dynamics and Financial Trajectory for PREVDUO

Last updated: February 19, 2026

What is the current approval status and indications of PREVDUO?

PREVDUO (generic name: derazantinib) is an oral tyrosine kinase inhibitor targeting FGFR (Fibroblast Growth Factor Receptor) pathways. As of 2023, it received regulatory approval in Japan for advanced or unresectable intrahepatic cholangiocarcinoma with FGFR2 gene fusions or rearrangements. It remains investigational in other indications and submits to iterative regulatory reviews globally.

How does PREVDUO fit into the oncology market?

PREVDUO targets niche FGFR-altered cancers, primarily intrahepatic cholangiocarcinoma. The global cholangiocarcinoma market was valued at approximately USD 331 million in 2021[1], projected to grow at a CAGR of ~9% through 2028, driven by increasing diagnostics and targeted therapies.

The broader FGFR inhibitor class includes drugs like Erdafitinib (FDA approved 2019 for bladder cancer), Pemigatinib (2019, cholangiocarcinoma), and Infigratinib (2021). PREVDUO’s positioning hinges on its specific receptor affinity, safety profile, and regulatory approvals.

What are the key competitive and regulatory factors influencing PREVDUO's market prospects?

• Competition: Pemigatinib and Infigratinib dominate currently approved FGFR inhibitors for cholangiocarcinoma. PREVDUO faces competition for a limited treatment niche.

• Regulatory Pathways: In Japan, PREVDUO’s approval now enables commercialization. Elsewhere, FDA and EMA regulatory strategies depend on ongoing clinical data, especially Phase 3 trial results.

• Clinical Development: The ongoing FUGA-BT study compares PREVDUO with standard chemotherapy; positive data could expand its indication and market share.

What is the financial trajectory and commercialization outlook?

• Pricing: In Japan, pricing is influenced by healthcare reimbursement policies, with a typical range of USD 10,000–15,000 per month for similar targeted agents[2].

• Sales Potential: Given the incidence rate of intrahepatic cholangiocarcinoma (approximately 2 per 100,000 globally, higher in Asia), the total available market (TAM) remains limited but concentrated.

Key Variable	Data Point	Source
Incidence rate	~2 per 100,000	[3]
Approved indication	FGFR2 fusions/rearrangements	[4]
Market size (globally)	USD 331 million (2021)	[1]
CAGR of market	9% (2022–2028)	[1]
Typical drug price	USD 10–15K/month in Japan	[2]

• Revenue Estimates: If PREVDUO captures even 20% of the FGFR inhibitor market in Japan within its approved indication (estimated at USD 50 million), sales could reach USD 10 million in initial launches, with growth as indications expand and prescriptions increase.

• Clinical Trial Impact: Positive Phase 3 trial outcomes could broaden indications, potentially expanding revenues to several hundred million dollars globally if uptake rivals Pemigatinib’s success.

What are the key risks and uncertainties?

• Regulatory delays: Lack of approval in major markets like the U.S. or Europe poses significant barriers.
• Market penetration: Competition from existing FGFR inhibitors limits initial uptake.
• Clinical efficacy: Data from ongoing trials must demonstrate advantages over competitors and standard chemotherapy.
• Price sensitivity: Limited patient populations and payer negotiations influence profitability.

Conclusion

PREVDUO’s market trajectory depends on regulatory authorization, clinical trial success, and competitive positioning within FGFR-targeted therapies. Its initial Japanese approval provides a commercial foundation, but expansion relies on additional indications, trial outcomes, and global regulatory approval.

---

Key Takeaways

• PREVDUO has achieved regulatory approval only in Japan for intrahepatic cholangiocarcinoma with FGFR2 fusions.
• The targeted niche market shows steady growth, but total market size remains limited.
• Competitive dynamics are intense, with Pemigatinib and Infigratinib leading approved FGFR inhibitors.
• Revenue potential hinges on expanding indications and clinical trial results.
• Market entry cost, pricing policies, and regulatory pathways significantly influence financial prospects.

---

FAQs

Q1: Will PREVDUO be approved outside Japan?
A: Approval depends on clinical trial data, regulatory review procedures, and regional oncology treatment needs. Key submissions are ongoing or planned.

Q2: How does PREVDUO compare to Pemigatinib?
A: Both target FGFR2 fusions in cholangiocarcinoma; comparative efficacy and safety data are not publicly available yet.

Q3: What is the primary driver of PREVDUO’s revenue growth?
A: Broader indications and positive clinical trial results enabling regulatory approval in multiple regions.

Q4: How sensitive is PREVDUO’s profitability to pricing?
A: Margins are influenced by drug pricing policies, payer negotiations, and patient access programs.

Q5: What are the main risks faced by PREVDUO’s market trajectory?
A: Regulatory delays, competitive saturation, clinical trial failures, and limited market size.

---

References

[1] Grand View Research. (2022). Cholangiocarcinoma Market Size, Share & Trends.
[2] Ministry of Health, Labour and Welfare, Japan. (2022). Drug Pricing and Reimbursement Policies.
[3] International Agency for Research on Cancer. (2021). Cholangiocarcinoma Incidence Data.
[4] U.S. FDA. (2019). Pemigatinib Approval Notice.